Table 1: Clinical trials with sorafenib in patients with thyroid cancers (according to Antonelli in modification3).
| author and year of the study | pathway inhibited | thyroid cancer | results (mPFS) | responses |
|---|---|---|---|---|
| Kober et al., 2007 | RAF, RET, VEGFR | 5 MTC | not reported | 1 (20 %) -PR, 1 (20 %) -CR |
| Gupta-Abramson et al. 2008 | RAF, RET, VEGFR | 30 DTC | 79 weeks | 7 (23 %) -PR, 16 (53 %) -SD |
| Kloos et al., 2009 | RAF, RET, VEGFR | 41 PTC, 11 FTC, 4 ATC |
15 months | 6 (15 %)-PR, 23 (56 %) -SD (PTC), no response (FTC and ATC) |
| Hoftijzner et al., 2009 | RAF, RET, VEGFR | 32 DTC | 58 weeks | 8 (25 %) -PR, 11 (34 %) -SD |
| Lam et al., 2010 | RAF, RET, VEGFR | 5 HMTC, 16 SMTC |
17,9 months | prematurely terminated HMTC, 1 (6 %)- PR, 14 (87%) -SD |
| Cabanillas et al., 2010 | RAF, RET, VEGFR E7080,VEGFR (sunitinib) |
8 PTC, 7 FTC (2 out of 15 received sunitinib) |
19 months | 3 (20 %)-PR, 9 (60 %)-SD |
| Ahmed et al., 2011 | RAF, RET, VEGFR | 15 MTC, 19 DTC |
not reached at 19 months | 24 (73 %)-SD |
| Capdevila et al., 2012 | RAF, RET, VEGFR | 7 PTC, 9 FTC, 15 MTC, 3 ATC |
13,5 months DTC, 10,5 months MTC, 4,4 months ATC |
11 (32 %)-PR, 14 (41 %)-SD |
| Savvides et al., 2012 | RAF, RET, VEGFR | 20 ATC | 1,9 months | 2 (10 %)-PR, 5 (25 %)-SD |
| Schneider et al., 2012 | RAF, RET, VEGFR | 26 DTC | 18 months | 8 (31 %)-PR, 11 (42 %)-SD |
(Abrrevations: MTC- medullary thyroid carcinoma, DTC- differentiated thyroid carcinoma, PTC- papillary thyroid carcinoma, FTC- follicular thyroid carcinoma, HMTC- hederitary medullary thyroid carcinoma, SMTC- sporadic medullary thyroid carcinoma, mPFS -median progression free survival).